



(51) International Patent Classification:

C07D 317/18 (2006.01) A61K 31/4164 (2006.01)
 C07D 233/56 (2006.01) A61K 31/423 (2006.01)
 C07D 261/08 (2006.01) A61K 31/4245 (2006.01)
 C07D 261/20 (2006.01) A61K 31/426 (2006.01)
 C07D 271/06 (2006.01) A61K 31/428 (2006.01)
 C07D 277/22 (2006.01) A61K 31/4402 (2006.01)
 C07D 277/66 (2006.01) C07D 231/12 (2006.01)
 C07D 213/04 (2006.01) C07D 333/06 (2006.01)
 A61K 31/357 (2006.01) C07D 271/10 (2006.01)
 A61K 31/381 (2006.01) A61P 21/00 (2006.01)
 A61K 31/415 (2006.01) A61P 21/04 (2006.01)

(21) International Application Number:

PCT/EP2018/084989

(22) International Filing Date:

14 December 2018 (14.12.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15/842,823 14 December 2017 (14.12.2017) US
 17207375.1 14 December 2017 (14.12.2017) EP

(71) Applicant: NMD PHARMA A/S [DK/DK]; c/o Capnova
Åbogade 15, 8200 Århus N (DK).

(72) Inventors: J.S. KNUTSEN, Lars; 10, Queens House, The Esplanade Frinton-on-Sea, Essex CO13 9AY (GB). KELLY, Nicholas; Højgårds Vænge 32, 2880 Bagsværd (DK). HOLM PEDERSEN, Thomas; Sejrs Allé 4A, 8240 Ris-skov (DK). E COOPER, Martin; 4 Greenwood Crescent Carlton, Nottingham NG4 1AQ (GB). W. BROWN, Andrew; Chestnut House, Brook Street, Heage, Derbyshire DE56 2AG (GB).

(74) Agent: HØIBERG P/S; Adelgade 12, 1304 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS




Fig. 1

(57) Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*